Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 20Active not recruiting 18Completed 6Terminated 4Withdrawn 3Not yet recruiting 2Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 2Lymphoma, Large B-Cell, Diffuse 1Cardiovascular Diseases 1

Interventions

venetoclax 6zanubrutinib 3tafasitamab 2obinutuzumab 2acalabrutinib 2Specimen Handling 2Rituximab 2Biopsy 2resiniferatoxin 1pirtobrutinib 1fludarabine 1duvelisib 1Therapeutics 1Sirolimus 1Prednisone 1Observation 1Magnetic Resonance Spectroscopy 1Interleukin-2 1Immunoglobulins 1Exercise 1Everolimus 1Disulfides 1Cyclophosphamide 1Blood Cell Count 1Biopsy, Needle 1Bendamustine Hydrochloride 1Azacitidine 1ARQ531 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia, Lymphocytic, Chronic, B-Cell × acalabrutinib × Clear all
NCT07582159 2026-05-12

Tafasitamab With Acalabrutinib and Venetoclax for the Treatment of Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

City of Hope Medical Center

Phase 2 Not yet recruiting
35 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07024706 2026-01-21

MAVRiC

AstraZeneca

Phase 2 Not yet recruiting
80 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphocytic, Chronic, B-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡